derazantinib

DRUG4 trials

Sponsors

Basilea Pharmaceutica, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Conditions

Combined Hepatocellular and CholangiocarcinomaGastric AdenocarcinomaIntrahepatic Cholangiocarcinoma

Phase 1

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

TerminatedNCT04604132

Basilea PharmaceuticaGastric Adenocarcinoma

Start: 2020-10-06End: 2022-11-21Updated: 2024-04-04

Phase 2

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

CompletedNCT03230318

Basilea PharmaceuticaCombined Hepatocellular and Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma

Start: 2017-09-28End: 2022-10-25Updated: 2023-12-19

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Active, not recruitingNCT05174650

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestIntrahepatic Cholangiocarcinoma

Start: 2022-04-20End: 2026-08-31Updated: 2025-12-05

Unknown Phase

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Basilea PharmaceuticaIntrahepatic Cholangiocarcinoma

Updated: 2025-04-06

Related Papers

Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating <i>FGFR1/2/3</i> genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.

Journal of Clinical Oncology2023-02-204 citations

Abstract 5501: Derazantinib, an FGFR1-3 inhibitor, inhibits CSF1R in macrophages and tumor cell lines, and synergizes with a PDL1-antibody in an FGFR-driven murine syngeneic model

Cancer Research2022-06-152 citations

Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01.

Journal of Clinical Oncology2022-01-1939 citations

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.

2020-11-1674 citations

Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.

2020-08-0632 citations

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements

Future Oncology2020-07-17158 citations

FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A).

Journal of Clinical Oncology2020-02-0111 citations

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

2018-11-13273 citations

Abstract LB-232: Derazantinib (ARQ 087) pharmacodynamics: Alterations in FGF19/21/23 and phosphate in patients with cholangiocarcinoma

Cancer Research2018-07-01